Background: Ductal adenocarcinoma of the pancreas is the fourth most common cause of death from cancer in men and women in Germany: about 15 000 persons die of this disease each year. Methods: The S3 guideline on exocrine pancreatic carcinoma was updated with the aid of systematic literature reviews on the surgical, neoadjuvant, and adjuvant treatment of ductal pancreatic carcinoma, and on treatment in the metastatic stage. These reviews covered the periods 2002 to February 2012 (for radiotherapy) and 2006 to August 2011 (for all other topics). Results: The criteria for borderline resectable pancreatic tumors are the same as those of the guidelines of the National Comprehensive Cancer Network. Preoperative biliary drainage with a stent is r...
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the i...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
One of the main reasons for the dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) is its l...
Pancreatic cancer is the third leading cause of cancer-related mortality in the US. Outcomes for pat...
Pancreatic adenocarcinoma is the fifth leading cause of cancer-related death in the U.S. In spite of...
Abstract. The management of pancreatic cancer has dramatically changed since the first major randomi...
Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patie...
Pancreatic cancer is the fourth leading cause of death for neoplasm in western countries. Surgery st...
The incidence of pancreatic cancer has been increasing in recent years. It is expected to be the sec...
The survival of patients with pancreatic cancer is dismal: tumor's resection is possible in only 10-...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the i...
The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases th...
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis....
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the i...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
One of the main reasons for the dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) is its l...
Pancreatic cancer is the third leading cause of cancer-related mortality in the US. Outcomes for pat...
Pancreatic adenocarcinoma is the fifth leading cause of cancer-related death in the U.S. In spite of...
Abstract. The management of pancreatic cancer has dramatically changed since the first major randomi...
Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patie...
Pancreatic cancer is the fourth leading cause of death for neoplasm in western countries. Surgery st...
The incidence of pancreatic cancer has been increasing in recent years. It is expected to be the sec...
The survival of patients with pancreatic cancer is dismal: tumor's resection is possible in only 10-...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the i...
The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases th...
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis....
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the i...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...